Research Project | LPI: Muhammad Muhammad Ismail Suleman
This project aims to develop an advanced AI-driven peptide engineering and validation platform to target
anti-apoptotic BCL-2 family proteins in colorectal cancer (CRC). Colorectal cancer remains a major global
health challenge, largely due to resistance to therapy caused by dysregulated apoptosis. Overexpression of
BCL-2 proteins allows cancer cells to evade cell death, highlighting the need for innovative therapeutic
strategies.
To address this, the proposed research integrates artificial intelligence, computational modeling, and
experimental validation to design novel pro-apoptotic peptides capable of restoring programmed cell death in
cancer cells. The platform will utilize cutting-edge AI approaches, including generative modeling and
inverse protein folding, followed by molecular docking, molecular dynamics simulations, and binding free
energy analysis to identify high-affinity peptide candidates.
Selected peptides will be further optimized and experimentally validated using colorectal cancer cell models
through assays such as MTT, flow cytometry, Western blotting, and biophysical techniques. Beyond developing
novel therapeutic candidates, the project aims to establish a scalable and reproducible AI-driven drug
discovery framework in Qatar, contributing to national biopharmaceutical innovation.
Figure: AI-powered generative design & validation pipeline (Phase 1–4) for
pro-apoptotic peptides.